$CLVS a growth business juices sg&a, only to reverse course in the third quarter to prudently manage expenses. short interest has 12mm swing in thirty days. executive options are repriced. the company does not even bother mentioning appearing at an industry conference, with results from a large pharma trial partner. dept repo. biggest trading volume increase in the history of the businesslast several months. secondary offerings, where investors always purchase the entire shoe. institutions taking 5% positions. conference calls where the sell-side rarely complains about the topline, despite fake news portraying slow growth. when it happens...
  • 3